Brandi, Maria Luisa http://orcid.org/0000-0002-8741-0592
Jan de Beur, Suzanne http://orcid.org/0000-0002-9386-7732
Briot, Karine http://orcid.org/0000-0002-6238-2601
Carpenter, Thomas http://orcid.org/0000-0003-1328-6768
Cheong, Hae Il http://orcid.org/0000-0001-7556-1265
Cohen-Solal, Martine http://orcid.org/0000-0002-8582-8258
Crowley, Rachel K. http://orcid.org/0000-0003-1472-4117
Eastell, Richard http://orcid.org/0000-0002-0323-3366
Imanishi, Yasuo http://orcid.org/0000-0002-9077-2631
Imel, Erik A. http://orcid.org/0000-0002-7284-3467
Ing, Steven W. http://orcid.org/0000-0002-4343-6723
Insogna, Karl http://orcid.org/0000-0001-6973-5679
Ito, Nobuaki http://orcid.org/0000-0002-4071-5372
Javaid, Kassim http://orcid.org/0000-0001-7985-0048
Kamenicky, Peter http://orcid.org/0000-0002-1994-4226
Keen, Richard
Kubota, Takuo http://orcid.org/0000-0003-4483-4405
Lachmann, Robin H. http://orcid.org/0000-0002-2618-2581
Perwad, Farzana http://orcid.org/0000-0001-7983-0127
Pitukcheewanont, Pisit
Portale, Anthony http://orcid.org/0000-0003-2054-6898
Ralston, Stuart H. http://orcid.org/0000-0002-2804-7586
Tanaka, Hiroyuki http://orcid.org/0000-0002-9117-3534
Weber, Thomas J. http://orcid.org/0000-0003-2868-2288
Yoo, Han-Wook http://orcid.org/0000-0001-8615-186X
Sun, Wei http://orcid.org/0000-0001-8161-6349
Williams, Angela
Nixon, Annabel http://orcid.org/0000-0003-3454-9491
Takeuchi, Yasuhiro http://orcid.org/0000-0002-0847-5233
Funding for this research was provided by:
Ultragenyx Pharmaceutical
Kyowa Kirin International
Article History
Received: 20 January 2022
Accepted: 5 July 2022
First Online: 4 August 2022
Declarations
:
: The following authors served as clinical investigators for one or more studies, including this trial, sponsored by Ultragenyx Pharmaceutical Inc. in partnership with Kyowa Kirin International plc: MLB, SJdB, KB, TOC, HIC, MC-S, RKC, RE, YI, EAI, KI, SI, NI, MKJ, PK, RK, TK, RHL, FP, PP, AAP, SHR, HT, TJW, H-WY, YT. SJdB, TOC, EAI, RHL, FP, AAP, and TJW have also received honoraria from Ultragenyx Pharmaceutical Inc. for serving as an advisory board member or for delivering lectures and AAP and TJW have received travel reimbursement. TOC, YI, MJK, RK, TK, and YT have received honoraria for serving as an advisory board member or for speaker fees from Kyowa Kirin International plc. During the past 3 years, the following authors have received grants outside of the submitted work: RE from Alexion Pharmaceuticals, Amgen, Immunodiagnostic Systems Holdings plc, Nittobo Medical Co., Ltd., and Roche; SI from Alexion Pharmaceuticals, Radius Health, and Takeda Pharmaceutical Company; NI, MJK, and RHL from Kyowa Kirin International plc; TK from Teijin Pharma; PP from Ultragenyx Pharmaceutical Inc.; and SHR from Amgen, UCB, and AstraZeneca. PP is currently an employee of Ascendis Pharma Inc. AW is an employee of Kyowa Kirin International plc and WS is an employee of Kyowa Kirin Pharmaceutical Development, Inc. AN and MN are employees of Chilli Consultancy and have received consultancy fees from Kyowa Kirin International plc to support the development of this manuscript and for projects outside this submitted work.
: As stated in the abstract, this study is a post hoc subgroup analysis from an approved phase 3 Clinical Trial (ClinicalTrials.gov NCT02526160) for which informed consent was obtained from all participants in the study.